Soligenix Inc. Completes U.S. Manufacturing Shift, Eyes Growth in GPCR-Therapy Market
Soligenix Inc. has successfully transferred its synthetic hypericin manufacturing process to the US, positioning the biotech company for growth in the GPCR-targeting therapies market.
3 minutes to read